Avanafil Market

The Avanafil market was valued at USD743.5 Mn by 2019. Significant rise in the geriatric population with erectile dysfunction and constant rise in an unhealthy lifestyle, the stress in the younger population resulting in reduced sex drive together determine the Avanafil market growth. The market restraint faced by Avanafil is from other commercially available phosphodiesterase-5 (PDE5) inhibitors such as Sildenafil, Tadalafil, and vardenafil.

The penile erection is a complex event that involves the integration of several factors such as neurologic, psychological, endocrine, vascular, etc. Anomaly associated with any of these events results in erectile dysfunction. Avanafil has an onset of action of 15 to 30 minutes which is relatively faster than other phosphodiesterase-5 (PDE5) inhibitors and thereby increases its popularity over other medicines. The mechanism of action associated with Avanafil is that it inhibits cGMP specific phosphodiesterase type 5 (PDE5) and thereby promotes penile erection during sexual drive. This response is caused by the release of nitric oxide from the endothelial cells and stimulates the synthesis of cyclic GMP which triggers smooth muscle relaxation and increases the blood flow in the corpus cavernosum region.

The major segments related to the Avanafil market are: 

By Demographics (2017–2027; US$ Mn)

21-39 years

40-59 years

Above 60 years

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

E-commerce

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global Avanafil market
• The overall segmentation of the Avanafil market, by demographics, distribution channel, and geography is minutely studied. Above 60 years and hospital pharmacy are dominating the demographics and distribution channel segments respectively
• Rising prevalence of erectile dysfunction in the elderly population worldwide and diabetes-induced impotency together drive the Avanafil market growth
• Excellent pharmacodynamics properties such as the fast onset of action and better tolerability in elderly population increases its popularity in comparison to other phosphodiesterase-5 (PDE5) inhibitors 

Report gist?

• The study of the global Avanafil market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of demographics and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 considering 2019 as the base year for the research. CAGR for each respective segments are calculated for the forecast period from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of Avanafilwhich is gaining huge demand owing to increasing impotency and erectile dysfunction in the adult population worldwide
• The report will benefit physicians engaged in prescribing Avanafil to patients as per their severity of erectile dysfunction
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to Avanafil market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

The elderly population above 60 years are leading the demographics segment for the Avanafil market. Erectile dysfunction is most widely encountered in this age group having variable causes associated with its etiology which are lower hormonal levels, neurogenic, psychogenic, and iatrogenic factors. The 21-39 age group demographics are set to witness rampant growth owing to the frequent occurrence of erectile dysfunction due to chronic alcoholism, smoking, type 2 diabetes which results in reduced blood supply to the corpus cavernosum smooth muscles of the penis and results in lower erection and cavernosal insensitivity.

Hospital pharmacies are currently dominating the distribution channel segment for Avanafil market. It is the first point of contact for patients to purchase drugs prescribed by their physicians. Pharmacists are skilled in dispensing the right dosage of medicine as per the patients’ body mass index reducing adverse events associated with high drug dosage. E-commerce segment is set to witness positive market growth during the forecast period owing to the adoption of smartphones by a huge customer base and capability to cater to the medical requirements of consumers of both urban and rural areas due to superior logistics.

North America is reigning the geography segment for the Avanafil market. As per the latest research citings brought forward by the pharmaceutical company Vivus, Inc., in the United States more than 30 million men are suffering from erectile dysfunction. Significant rise in diabetic men population with reduced sex drive and increasing stress together drive the Avanafil market growth in the region. According to the European Association of Urology, the prevalence rate of erectile dysfunction in Europe is 19.2% and is anticipated to rise in the near future owing to the significant rise in obesity and heart diseases. The Asia Pacific is anticipated to grow at a rapid pace during the forecast period and provides a lucrative market for Avanafil on account of the huge geriatric population and market expansion opportunities by entering into a potential licensing agreement with local players holding significant customer base suffering from erectile dysfunction.